AnaptysBio, Inc.

General ticker "ANAB" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $1.0B (TTM average)

AnaptysBio, Inc. follows the US Stock Market performance with the rate: 49.0%.

Estimated limits based on current volatility of 2.8%: low 50.92$, high 53.82$

Factors to consider:

  • Total employees count: 142 as of 2024
  • Top business risk factors: Manufacturing process failures, Insufficient funding, Supply chain disruptions, Regulatory and compliance, Market volatility
  • Earnings for 3 months up through Q1 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

  • 2025-12-31 to 2026-12-31 estimated range: [19.84$, 46.58$]
  • 2026-12-31 to 2027-12-31 estimated range: [14.44$, 35.34$]

Financial Metrics affecting the ANAB estimates:

  • Negative: with PPE of -62.9 at the end of fiscal year the price was very high
  • Positive: Operating profit margin, % of 20.42 > 18.39
  • Positive: -3.75 < Return on assets ratio (scaled to [-100,100]) of -3.50
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Positive: -0.02 < Operating cash flow per share per price, % of 2.17
  • Negative: -0.75 < Inventory ratio change, % of 0
  • Negative: Industry earnings per price (median), % of -13.66 <= 0
  • Positive: Investing cash flow per share per price, % of 25.10 > -0.60

Similar symbols

Short-term ANAB quotes

Long-term ANAB plot with estimates

Financial data

YTD 2023-12-31 2024-12-31 2025-12-31
Operating Revenue $17.16MM $91.28MM $234.60MM
Operating Expenses $181.57MM $206.23MM $186.71MM
Operating Income $-164.41MM $-114.95MM $47.90MM
Non-Operating Income $0.79MM $-30.28MM $-60.96MM
R&D Expense $132.28MM $163.84MM $135.97MM
Income(Loss) $-163.62MM $-145.23MM $-13.07MM
Taxes $-0.00MM $0.00MM $0.16MM
Net Income(Loss)* $-163.62MM $-145.23MM $-76.08MM
Stockholders Equity $88.10MM $70.87MM $37.21MM
Assets $452.39MM $483.83MM $364.39MM
Operating Cash Flow $-120.80MM $-135.34MM $19.70MM
Capital expenditure $0.81MM $0.36MM $0.09MM
Investing Cash Flow $144.75MM $95.40MM $228.03MM
Financing Cash Flow $-59.30MM $127.05MM $-132.61MM
Earnings Per Share** $-6.08 $-5.12 $-2.74

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.